Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Case
-
Reference no. 9-294-005
Published by: Harvard Business Publishing
Originally published in: 1993
Version: 20 July 1993
Length: 18 pages
Data source: Field research

Abstract

Genzyme Corp's financing history is unusual compared to most biotech companies. This case presents the sequence of financings employed by Genzyme, along with the product - market and corporate-development strategies adopted by Henri Termeer, Genzyme's CEO. As such, the case permits students to evaluate the sequence of financings as a 'program' rather than a series of unrelated deals and to consider them in light of the business strategy.
Location:
Industry:
Size:
USD220 million revenues
Other setting(s):
1983-1993

About

Abstract

Genzyme Corp's financing history is unusual compared to most biotech companies. This case presents the sequence of financings employed by Genzyme, along with the product - market and corporate-development strategies adopted by Henri Termeer, Genzyme's CEO. As such, the case permits students to evaluate the sequence of financings as a 'program' rather than a series of unrelated deals and to consider them in light of the business strategy.

Settings

Location:
Industry:
Size:
USD220 million revenues
Other setting(s):
1983-1993

Related